블로그
- 릴리 경구GLP1제제, Orforglipron 3상 연구 발표 −11.2% weight loss at 72 weeks with highest dose vs. −2.1% with placebo >50% of patients hit ≥10% weight loss 1 in 5 patients achieved ≥20% weight loss Improved waist size, blood pressure, triglycerides
- A Bayesian network meta-analysis of EGFR-tyrosine kinase inhibitor treatments in patients with ... A Bayesian network meta-analysis of EGFR-tyrosine kinase inhibitor treatments in patients with EGFR mutation-positive This study aimed to investigate the efficacy and safety of EGFR-TKIs in patients with EGFR mutation-positive
- Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2− breast cancer 6) inhibitors, which are dependent on cell cycle proteins, has greatly enhanced the prognosis of patients with advanced HR+/HER2− breast cancer.
- Impacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in ... Impacts of genomic alterations on the efficacy of HER2-targeted antibody–drug conjugates in patients with metastatic breast cancer and perfor.......
- Overall survival after CDK4/6 inhibitor dose reduction in women with metastatic breast cancer Breast cancer is the most common cancer in women, and the first-line treatment for patients with hormone-receptor All women with metastatic breast cancer initiating first-line t.......
- Cardiovascular, cancer, and infection risks of Janus kinase inhibitors in rheumatoid arthritis ... Abstract Background Evolving evidence suggests that patients undergoing treatment with Janus kinase inhibitors with rheumatoid arthritis (RA) or ulcerative colitis (UC).
- 운동사 ; 카셉(kacep) 시험 - 질환별 FITT 운동처방 2) Exercise Testing and Prescription & Exercise Prescription for Patients with Diseases (다음 환자를 위한
- CENSUS-TRACT-LEVEL PRIVATE WELL WATER EXPOSURE & PROSTATE CANCER MORTALITY RISK These exposures may influence survival in cancer patients. We studied whether census tracts with high private well water exposure were associated with differences
- RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ ... : Combined CDK4/6 inhibitor (CDK4/6i) and endocrine therapy significantly improve the outcome of patients with advanced estrogen receptor-positive (ER+) breast cancer.
- Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients ... Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor-Positive Advanced Breast Cancer Purpose: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) combined with